News Releases Optinose Q2 2022 Earnings Call Thursday, August 11, 2022 at 8:00 AM EDT Listen to Webcast Keyword Search Year None20222021202020192018 Date Title 08/11/22 Optinose Reports Second Quarter 2022 Financial Results and Operational Updates 08/08/22 Optinose Announces Reporting Date for Second Quarter 2022 Financial Results 07/13/22 Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program 07/08/22 Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program 06/13/22 Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis 06/03/22 Optinose Announces Departure of Chief Financial Officer 05/12/22 Optinose Reports First Quarter 2022 Financial Results and Operational Updates 05/05/22 Optinose Announces Reporting Date for First Quarter 2022 Financial Results 04/26/22 Optinose Announces Appointment of R. John Fletcher to the Board 04/08/22 Optinose to Present at the Needham Virtual Healthcare Conference 03/08/22 Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights 03/07/22 Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis 03/04/22 Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results